Glialogix 20logo3


Glialogix offers a unique opportunity in Progressive Multiple Sclerosis, a multi-billion dollar market with no effective therapies.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location San Francisco, CA, US
  • Currency USD
  • Founded June 2012
  • Employees 3
  • Website

Company Summary

Our mission is to develop GLX1112 as a breakthrough therapy for progressive multiple sclerosis, a devastating disease with no effective treatments. GLX1112 is an improved formulation of an FDA-approved drug that has previously shown a large efficacy signal in progressive MS patients. Our therapeutic approach is neuroprotective and designed to slow the accumulation of disability by reducing chronic damage to neurons and oligodendrocytes.


  • Aa2decad fe03 4af6 8a31 20b29f292628
    Co-founder and Chief Scientific Officer

    Dr. Reeder has 18 years of experience in the biotechnology field, with extensive experience in technology development, target identification and validation, project management and intellectual property. Dr. Reeder previously co-founded Toccata Therapeutics, the first company to develop rapid in vivo drug screening technologies for protein therapeutics. Dr. Reeder received his Ph.D. in molecular biology from Brandeis University.

  • 745f6811 4f98 44ab 89c4 5a5d602c9fe2
    Chief Executive Officer

    Dr. Moore has over 22 years of experience in the biotechnology industry, beginning at Genentech, where he ran the mouse knockout and target validation program. He also co-founded Deltagen, which grew to over 400 employees and had a market capitalization of more than $1B at its peak. Dr. Moore received his Ph.D. in molecular biology and immunology from Brandeis University and his A.B. degree in biochemical sciences from Princeton University.